OVARIAN CANCER and US: treatment response

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label treatment response. Show all posts
Showing posts with label treatment response. Show all posts

Saturday, April 14, 2012

abstract: Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer



Prognostic factors associated with response in platinum retreatment of platinum-resistant ovarian cancer:

Abstract

The goal of this study was to determine the factors associated with response to platinum retreatment in patients with platinum-resistant ovarian cancer. A review of patients with epithelial ovarian cancer retreated with cisplatin or carboplatin between 2002 and 2004 was performed. The platinum-free interval (PFI) and treatment-free interval (TFI) were determined for each patient. Response was based on serial CA125 levels using a modification of the Rustin criteria. Patients with clinical benefit ([CB] those who attained at least stable disease) were compared to patients with disease progression (PD). An analysis was performed to determine factors associated with CB in platinum-resistant patients retreated with platinum. Of 48 patients identified, 37 were evaluable included in this analysis. CB was observed in 27 (73%) while disease progression was noted in 10 (27%) women. The PFI was longer in those women who achieved CB (12.3 vs 6.9 months; P = 0.02). The TFI was 7.1 months for patients benefited from platinum retreatment vs 3.5 months for those with disease progression (P = 0.06). There was no statistically significant difference in the number of cytotoxic agents between the time of platinum retreatment and the prior platinum regimen (2 vs 1.5 months; P = 0.61). A prolonged PFI was associated with an improved chance of achieving CB with platinum retreatment. There was no association between the response to platinum retreatment and the number of intervening cytotoxic agents utilized. Further prospective study is warranted to define the optimal timing of platinum retreatment.

Friday, April 23, 2010

In research: Medical News: AACR: Gene Copy Number May Predict Success in Ovarian Cancer - in Meeting Coverage, AACR from MedPage Today



Note: in research:
WASHINGTON -- The number of copies of certain genes -- especially those that are associated with apoptosis -- may signal whether a patient with ovarian cancer will respond to therapy, researchers suggested here.